Drug
Radiolabeled Dpta Omburtamab
Radiolabeled Dpta Omburtamab: highest development phase Phase 1/2, developed by Y-mAbs Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| radiolabeled DPTA-omburtamab NCT04315246 | Phase 1/2 | Leptomeningeal Metastasis |
Latest
No recent events.
Follow Radiolabeled Dpta Omburtamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.